Asco 2023 preview – Tigit lives again
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
The quiet resurgence of Cellular Biomedicine
Cellular Biomedicine Group has had a rollercoaster existence, and emerged from obscurity this week with a $245m injection from J&J.
After Mariposa a Carvykti leak brings J&J better news
No news is bad news for the Mariposa trial, J&J’s bid for market share in lung cancer, but Carvykti turns the frown upside down.
AACR 2023 – Regeneron tries again in multiple myeloma
If at first you don’t succeed... Regeneron follows the underwhelming linvoseltamab with something it hopes will be better.
Remarkably, interest in BCMA continues
But, as Celyad bows out, how do you compete in a field as crowded as this?
J&J’s $5bn projects have much to prove
The group highlighted Carvykti, nipocalimab and milvexian among its potential mega-blockbusters.